Drug - Fenofibrate
Therapeutic area - Cardiovascular
||Nonpreferred - PA required (all are fenofibrate)
|Tricor 48 mg, 145 mg
Trilipix 45 mg, 135 mg
Fenofibrate (tablets and capsules)
Fibricor (35mg, 105mg)
Patient does not receive adequate triglyceride lowering from the preferred fenofibrates or has allergy or intolerance to a preferred fenofibrate.
DHS is not proposing that patients be switched from a branded fenofibrate to gemfibrozil.
There is no evidence to support superior efficacy of any one brand in this class.
Each of these brands has the same FDA indication:
- Indicated as adjunctive therapy to diet for the reduction of LDL-C, Total C, triglycerides, and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidema (Fredrickson Types IIa and IIb).
Each of these brands is dosed once daily.
See Grandfathering Criteria – which indicate patient specific criteria that would exclude a patient from switching to a preferred drug.
MHCP Provider Call Center 651-431-2700 or 800-366-5411